Joint venture · GCC · Announced 8 Nov 2026
Oman Investment Authority → Oryx Isotopes
Oman Investment Authority and Saudi Arabia's Oryx Isotopes launched Nucleus Oman, a joint venture to build Oman's first radiopharmaceutical production facility under a long-term PPP concession with the Ministry of Health, reported at OMR 6.5 million.
Parties: Oman Investment Authority (Oman) → Oryx Isotopes Company (Saudi Arabia)
- Deal type
- Joint venture
- Value
- $17m
- Territory
- Oman
- Therapeutic area
- Multi-therapy
- Assets
- Diagnostic radiopharmaceuticals; Targeted radionuclide therapy preparations
- Announced
- 8 Nov 2026
Our analysis
Why this matters
Oman launched Nucleus Oman on 8 November 2026, the Sultanate's first radiopharmaceutical manufacturing project. A joint venture between the Oman Investment Authority (OIA) and Saudi Arabia's Oryx Isotopes Company will develop and operate it as concessionaire under a long-term public-private partnership with the Ministry of Health. The Ministers of Finance and Health and OIA President Abdulsalam bin Mohammed al Murshidi announced the project. WA-Gulf reports the investment at OMR 6.5 million (about US$17 million); the other reports give no figure, and none gives a location or timeline.
The facility will produce diagnostic radiopharmaceuticals for nuclear-medicine imaging in cancer, cardiovascular and neurological disease, with further units for targeted radionuclide therapy. It will also house a Secondary Standard Dosimetry Laboratory for calibrating radiation instruments, plus research and training facilities. The stated aim is to cut reliance on imports and give public and private hospitals a domestic supply.
The full analysis is free to read with a work email on this page.
Source: Oman Observer